What Intensity Therapeutics does

Intensity Therapeutics is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Shelton, Connecticut. The company is developing first-in-class intratumoral cancer therapies based on its proprietary DfuseRx discovery platform, which enables direct injection of drug formulations into solid tumors with high dispersion and cell penetration. Its lead product candidate, INT230-6, is a three-component water-based formulation combining cisplatin, vinblastine sulfate, and the proprietary amphiphilic penetration enhancer SHAO (8-((2-hydroxybenzoyl)amino)octanoate). More than 95% of the active ingredients remain in the injected tumor, reducing systemic toxicity while the localized cell death is intended to trigger a systemic adaptive immune response against both injected lesions and distant micro-metastases. The company has been listed on Nasdaq under the ticker INTS since June 30, 2023, operates with a lean team of approximately 7 employees, and holds 19 issued patents across 41 countries.

The company's clinical program targets underserved oncology indications with limited treatment options. The lead program is the Phase 3 INVINCIBLE-3 study in locally recurrent, inoperable, or metastatic soft tissue sarcoma (paused since March 2025 due to funding), the Phase 2 INVINCIBLE-4 neoadjuvant study in triple-negative breast cancer (TNBC), and the Phase 1/2 IT-01 dose-finding study in multiple refractory solid tumors including pancreatic, bile duct, colorectal, and liver cancers. Over 200 patients have been enrolled in clinical trials since 2017, with reported signals including 71.4% pathological complete response in TNBC when INT230-6 is added to standard of care, a 75% disease control rate in IT-01, and median overall survival of 649-715 days in sarcoma versus 205 days historical control. The platform has been validated through clinical collaborations with Merck (KEYTRUDA combination, 2019), Bristol Myers Squibb (Yervoy combination, 2020), and the National Cancer Institute under a CRADA signed in 2014.

Intensity Therapeutics is pre-revenue and does not currently commercialize any product. Revenue is expected to be generated through pharmaceutical product sales and/or partnership licensing following regulatory approval of INT230-6. As of the most recent disclosures, cash and cash equivalents stood at $10.2 million (Q1 2026) against a 2025 net loss of $11.6 million, with management indicating a runway into Q2 2027. Distribution currently occurs through clinical trial sites (approximately 16 sites planned for INVINCIBLE-4 in the U.S., Switzerland, and France), with no commercial sales infrastructure in place. The company has stated it is actively pursuing partnership or acquisition transactions with larger pharmaceutical companies to advance the program through regulatory approval.

Name

Intensity Therapeutics

Legal name

Intensity Therapeutics, Inc.

Website

https://intensitytherapeutics.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Intensity Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: INTS) developing INT230-6, a proprietary intratumoral injection therapy using its DfuseRx platform to treat refractory solid tumors including sarcoma and triple-negative breast cancer. The company is pre-revenue with no commercial customers.

Ownership category

akta.pro rank

Product category

Intratumoral Immuno-Oncology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Intratumoral cancer therapy
• Clinical-stage biotechnology
• Immuno-oncology drugs
• Drug delivery platform
• Solid tumor treatment

Headquarters

HQ city

Norwalk

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech. If INT230-6 receives regulatory approval, the company would generate revenue through direct pharmaceutical product sales for intratumoral cancer treatment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Intensity Therapeutics is a clinical-stage biotechnology company developing INT230-6, a proprietary investigational drug formulation combining cisplatin and vinblastine with the SHAO cell penetration enhancer for direct intratumoral injection into solid tumors. Its DfuseRx platform produces water-based drug solutions that disperse throughout injected tumors and, via localized cell death, activate systemic adaptive immune responses against both injected and non-injected tumors including micro-metastases. INT230-6 is currently in Phase 3 testing for soft tissue sarcoma and Phase 2 testing for triple-negative breast cancer, with next-generation candidate INT33X in preclinical development.

Product overview

Intensity Therapeutics is a clinical-stage biotechnology company developing a proprietary intratumoral cancer therapy platform. The core product is INT230-6, a novel drug formulation combining cisplatin and vinblastine with a cell penetration enhancer (SHAO), administered via direct tumor injection. The company's DfuseRx technology platform enables creation of novel cell-penetrating formulations for solid tumor treatment. INT230-6 is currently undergoing Phase 3 testing in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer, with next-generation product INT33X in preclinical development.

Differentiator

Problem solved

Functional benefit

Brands

• DfuseRx: Proprietary product discovery technology platform that enables drug compounds to be injected directly into solid tumors with high absorption using novel dispersion and cell penetration enhancer molecules
• INT230-6

Products and services

• INT230-6 Lead proprietary investigational product candidate designed for direct intratumoral injection, composed of cisplatin and vinblastine combined with the SHAO penetration enhancer that disperses cytotoxic drugs throughout tumors and enables diffusion into cancer cells. IND authorized by FDA, currently in Phase 3 testing in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer.
• DfuseRx Platform Proprietary product discovery technology platform that enables drug compounds including cytotoxic agents to be injected directly into solid tumors with high absorption using novel dispersion and cell penetration enhancer molecules. The platform underpins INT230-6 and the next-generation pipeline asset INT33X.
• INT33X Next-generation product candidate in preclinical development, part of the company's pipeline for intratumoral cancer therapy using the DfuseRx platform.

Quantifiable outcome

• 71.4% pathological complete response (pCR) in TNBC patients receiving INT230-6 plus SOC vs 33% for SOC alone in INVINCIBLE-4 study
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Ottawa Hospital Research Institute (OHRI)coreStrategic or Co-development Partner · 1 March 2021Conducted subject enrollment and treatment for INVINCIBLE Phase 2 presurgical breast cancer study, evaluating pathological and clinical responses under the direction of Principal Investigator Dr. Angel Arnaout.
• Ontario Institute for Cancer Research (OICR)coreStrategic or Co-development Partner · 1 March 2021Analyzing subject immune responses and conducting biomarker analyses for the INVINCIBLE Phase 2 study. Co-director Dr. Melanie Spears leads the diagnostic development work.
• Bristol Myers SquibbcoreStrategic or Co-development Partner · 14 April 2020Clinical collaboration to evaluate INT230-6 in combination with Yervoy (ipilimumab), BMS's anti-CTLA-4 antibody, in patients with breast cancer, liver cancer, and advanced sarcoma. Joint development committee manages the collaboration.
• Merck & Co. (MSD outside US/Canada)coreStrategic or Co-development Partner · 25 June 2019Clinical collaboration to evaluate INT230-6 in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced pancreatic, bile duct, squamous cell, and non-MSI high colon cancers. Part of the IT-01 KEYNOTE-A10 study arm.
• National Cancer Institute (NCI)/National Institutes of HealthcoreStrategic or Co-development Partner · 1 January 2014Cooperative Research and Development Agreement (CRADA) with NCI Vaccine Branch to study efficacy and mechanism of action of Intensity's in situ tumor killing products. Two peer-reviewed publications resulted from this collaboration, including work published in International Journal of Molecular Sciences and OncoImmunology.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Nanobiotix: Nanobiotix develops NBTXR3 (hafnium oxide nanoparticles) for intratumoral injection to enhance radiotherapy in solid tumors, representing a directly comparable intratumoral modality. Both companies are pursuing local tumor-directed intervention with systemic implications for hard-to-treat solid tumors.
• Candel Therapeutics: Candel Therapeutics develops CAN-2409, an intratumoral gene-mediated immunotherapy for prostate cancer and high-grade glioma, sharing Intensity's intratumoral injection approach with viral vector delivery. Both target refractory solid tumors with a local injection mechanism designed to drive systemic immune effects.
• Replimune Group: Replimune develops intratumoral oncolytic virus therapies (RP1, RP2, RP3) that combine local tumor killing with systemic immune activation, sharing Intensity's mechanism rationale of localized treatment triggering abscopal immune effects in solid tumors. Both companies target similar refractory cancer indications and pursue Big Pharma combination strategies.
• OncoSec Medical (Sirenomed): OncoSec develops intratumoral electroporation-delivered IL-12 immunotherapy (TAVO), a directly comparable intratumoral delivery approach for solid tumors including melanoma and breast cancer. Both companies focus on local injection with systemic immune engagement as the core value proposition.

Emerging players

• Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies (afami-cel, lete-cel) for solid tumors including sarcoma. Different modality from Intensity but addresses overlapping sarcoma and refractory solid tumor patient populations.
• Iovance Biotherapeutics: Iovance develops tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors, with FDA-approved lifileucel for melanoma. Different delivery modality (cell therapy vs intratumoral injection) but shares the target indication space of refractory solid tumors.
• Targovax: Targovax develops ONCOS-102, an oncolytic adenovirus for intratumoral injection in mesothelioma and other solid tumors. Shares the intratumoral immunotherapy mechanism of action with Intensity Therapeutics, though focused on different lead indications.
• Phio Pharmaceuticals: Phio Pharmaceuticals develops INTASYL self-delivering RNAi technology for intratumoral delivery, including lead asset PH-762 administered intratumorally for solid tumors. Overlapping intratumoral delivery modality for oncology indications with smaller scale and earlier clinical stage than Intensity.

Broad incumbents

• Merck & Co. Merck is a broad oncology incumbent with Keytruda franchise and an existing clinical collaboration with Intensity on INT230-6 combinations. Comparable as the largest immuno-oncology player whose combination strategy defines the standard of care that intratumoral therapies must integrate with.
• Bristol Myers Squibb: Bristol Myers Squibb is a broad oncology incumbent with Yervoy and Opdivo franchises and an active clinical collaboration with Intensity evaluating INT230-6 combinations. Comparable as a major checkpoint inhibitor sponsor whose assets form the combination backbone for intratumoral therapies.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/IntensityInc
• LinkedInlinkedin.com/company/intensity-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intensity Therapeutics